Analytical Data
-
Gene name
DLL3
-
简介
Delta-like protein 3/DLL3 stands out as a key regulator of neurogenesis and cell differentiation. As an inhibitor of primary neurogenesis, DLL3 plays a crucial role in guiding neurons along specific differentiation pathways. Delta-like protein 3/DLL3 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Delta-like protein 3/DLL3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Application
-
Alternative Names
Delta3; DLL3; Pudgy; SCDO1; SCDO1delta3
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NYJ7-1
-
Expression Region
V311-A479
-
Protein Length
Partial
-
Molecular Weight
25-30 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DLL3 (Delta-like ligand 3) is a member of the Notch signaling pathway, primarily involved in cell differentiation and development. Its expression is notably restricted to certain neuroendocrine tumors, particularly small cell lung cancer (SCLC), making it a potential target for therapeutic interventions. Research has revealed that DLL3 acts as an oncofetal antigen, which is abundantly expressed in tumor cells while being minimally present in normal tissue. This unique expression pattern has prompted investigations into DLL3 as a biomarker for diagnosis and a target for targeted therapies, such as antibody-drug conjugates. Recombinant DLL3 protein has been essential for these studies, enabling the development of assays to measure DLL3 expression and facilitating the exploration of DLL3-targeted therapeutic strategies. Understanding the functional role of DLL3 in tumor biology and its potential implications in therapeutic context is crucial for advancing cancer treatment, especially for aggressive malignancies like SCLC. Therefore, ongoing research aims not only to elucidate the biological functions of DLL3 but also to evaluate its efficacy as a target for novel cancer therapies, including immunotherapy approaches, enhancing the hope for improved clinical outcomes in patients with DLL3-expressing tumors.
